Worsening of motor function in Parkinson’s disease
A “typical” response to “atypical” antipsychotic medications
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Neuroleptic medications, which block dopamine receptors, are effective antipsychotic agents. They have, however, been fraught with adverse effects, particularly extrapyramidal syndromes (EPS). The new generation of antipsychotics are referred to as “atypical” antipsychotics because their antipsychotic actions are rarely associated with acute or subacute EPS in psychiatric populations.1
Psychosis occurs in approximately 20% of patients with PD who are treated with antiparkinsonian agents, and is the number one cause of nursing home placement.2 Patients with PD are, however, extremely sensitive to antidopaminergic actions of drugs. Until fairly recently, clinicians attempting to treat drug-induced psychosis in PD were in a quandary. Potential treatment strategies were limited to the equally unsatisfactory options of reducing the antiparkinsonian medications or using a neuroleptic, both of which generally worsened motor function.
Recently, the “atypical” antipsychotic clozapine …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Alert Me
Recommended articles
-
BRIEF COMMUNICATIONS
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's diseaseE.Ch. Wolters, E.N.H. Jansen, H. G. Tuynman-Qua et al.Neurology, October 01, 1996 -
Review
PimavanserinA novel therapeutic option for Parkinson disease psychosisTrevor Hawkins, Brian D. Berman et al.Neurology: Clinical Practice, March 24, 2017 -
Articles
Quetiapine for agitation or psychosis in patients with dementia and parkinsonismRoger Kurlan, Jeffrey Cummings, Rema Raman et al.Neurology, April 23, 2007 -
Views & Reviews
Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warningJoseph H. Friedman et al.Neurology, August 21, 2006